Characterization of chemoresistant human non-small cell lung cancer cells by metabolic and lipidomic profiling.
Level 5 - mechanism / opinion, no new human data
Bench research / in vitro cell culture study with no human clinical data
PubMed 37690093 · doi:10.1007/s11306-023-02045-3
What was done
Researchers established a doxorubicin-resistant non-small cell lung cancer (NSCLC) cell line (A549/CR) by exposing parental A549 cells to increasing drug concentrations (0.03 to 0.5 µM) over 3 months. Reactive oxygen species (ROS) levels and expression of glutathione peroxidase (GPX) family members and multidrug resistance protein 1 (MRP1) were assessed via real-time PCR and Western blotting. Gas chromatography-mass spectrometry and nano-electrospray ionization mass spectrometry with multivariate statistical analysis were used to profile metabolic and lipidomic changes.
What was found
In resistant A549/CR cells, ROS levels decreased, while GPX2 and MRP1 mRNA and protein expression increased compared to parental A549 cells. The profiling identified 87 metabolites and intact lipid species; alterations in lactic acid, glutamic acid, glycine, proline, aspartic acid, succinic acid, ceramide, the phosphatidylcholine-to-phosphatidylethanolamine (PC to PE) ratio, and arachidonic acid-containing phospholipids characterized the resistant cells. Exact numerical values and effect sizes were not reported in the abstract.
Why it matters
This study maps specific metabolic and lipidomic shifts linked to acquired chemoresistance in lung cancer cells. These identified pathways suggest potential targets for developing therapeutic strategies to counter drug resistance.
Limits
The study is entirely in vitro, using a single cell line model (A549) without animal or patient sample validation. No quantitative effect sizes or variance statistics are provided in the abstract.
Cited by
- supports Lactic acid and succinic acid produced by tumor fermentation protect tumor cells from chemotherapy and radiation.